Revenue Update on Omnicell(NASDAQ:OMCL)

Omnicell(NASDAQ:OMCL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $175.57M. Analysts estimated a revenue of $170.89M. Earnings per share were $0.38. Analysts had estimated an EPS of $0.32.

Omnicell (OMCL) made into the market gainers list on Thursdays trading session with the shares advancing 0.13% or 0.05 points. Due to strong positive momentum, the stock ended at $37.95, which is also near the day’s high of $38.206. The stock began the session at $37.95 and the volume stood at 1,59,756 shares. The 52-week high of the shares is $40.24 and the 52 week low is $25.06. The company has a current market capitalization of $1,363 M and it has 3,59,17,793 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Robin Gene Seim (EVP, Global A & M Adherence) sold 5,302 shares at $34.75 per share price.Also, On Jun 6, 2016, Jorge R. Taborga (Executive VP. Engineering) sold 25,979 shares at $33.00 per share price.On May 25, 2016, Gary S Petersmeyer (director) sold 6,250 shares at $31.22 per share price, according to the Form-4 filing with the securities and exchange commission.

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.